다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기
Korean circulation journal, v.48 no.11, 2018년, pp.951 - 963
Han, Ki Hoon (Department of Internal Medicine, College of Medicine Ulsan University, Asan Medical Center, Seoul, Korea .)
AI-Helper
HMG-CoA reductase inhibitors, i.e. statins, are effective in reducing cardiovascular disease events but also in cardiac-related and overall mortality. Statins are in general well-tolerated, but currently the concerns are raised if statins may increase the risk of new-onset diabetes mellitus (NOD). I...
1 Endo A Hasumi K Biochemical aspect of HMG CoA reductase inhibitors Adv Enzyme Regul 1989 28 53 64 2696346
2 Stone NJ Robinson JG Lichtenstein AH 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2014 63 2889 2934 24239923
3 Augustin R The protein family of glucose transport facilitators: it's not only about glucose after all IUBMB Life 2010 62 315 333 20209635
4 Nordlie RC Foster JD Lange AJ Regulation of glucose production by the liver Annu Rev Nutr 1999 19 379 406 10448530
5 Keembiyehetty C Augustin R Carayannopoulos MO Mouse glucose transporter 9 splice variants are expressed in adult liver and kidney and are up-regulated in diabetes Mol Endocrinol 2006 20 686 697 16293642
6 McVie-Wylie AJ Lamson DR Chen YT Molecular cloning of a novel member of the GLUT family of transporters, SLC2a10 (GLUT10), localized on chromosome 20q13.1: a candidate gene for NIDDM susceptibility Genomics 2001 72 113 117 11247674
7 Elliott KR Bate AJ Craik JD Specificity of the rat hepatocyte monosaccharide transporter Int J Biochem 1984 16 1251 1253 6543347
8 Leturque A Brot-Laroche E Le Gall M GLUT2 mutations, translocation, and receptor function in diet sugar managing Am J Physiol Endocrinol Metab 2009 296 E985 92 19223655
9 Fraulob JC Souza-Mello V Aguila MB Mandarim-de-Lacerda CA Beneficial effects of rosuvastatin on insulin resistance, adiposity, inflammatory markers and non-alcoholic fatty liver disease in mice fed on a high-fat diet Clin Sci (Lond) 2012 123 259 270 22420611
10 Tappy L Dussoix P Iynedjian P Abnormal regulation of hepatic glucose output in maturity-onset diabetes of the young caused by a specific mutation of the glucokinase gene Diabetes 1997 46 204 208 9000695
11 Steele AM Wensley KJ Ellard S Use of HbA1c in the identification of patients with hyperglycaemia caused by a glucokinase mutation: observational case control studies PLoS One 2013 8 e65326 23799006
12 Iynedjian PB Pilot PR Nouspikel T Differential expression and regulation of the glucokinase gene in liver and islets of Langerhans Proc Natl Acad Sci U S A 1989 86 7838 7842 2682629
13 Hegarty BD Bobard A Hainault I Ferré P Bossard P Foufelle F Distinct roles of insulin and liver X receptor in the induction and cleavage of sterol regulatory element-binding protein-1c Proc Natl Acad Sci U S A 2005 102 791 796 15637161
14 Kim TH Kim H Park JM Interrelationship between liver X receptor alpha, sterol regulatory element-binding protein-1c, peroxisome proliferator-activated receptor gamma, and small heterodimer partner in the transcriptional regulation of glucokinase gene expression in liver J Biol Chem 2009 284 15071 15083 19366697
15 Pramfalk C Parini P Gustafsson U Sahlin S Eriksson M Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism J Intern Med 2011 269 333 339 21083855
16 O'Doherty RM Lehman DL Télémaque-Potts S Newgard CB Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia Diabetes 1999 48 2022 2027 10512368
17 Chakera AJ Steele AM Gloyn AL Recognition and management of individuals with hyperglycemia because of a heterozygous glucokinase mutation Diabetes Care 2015 38 1383 1392 26106223
18 Schonewille M de Boer JF Mele L Statins increase hepatic cholesterol synthesis and stimulate fecal cholesterol elimination in mice J Lipid Res 2016 57 1455 1464 27313057
19 Tsai AC Dyer IA Influence of dietary cholesterol and cholic acid on liver carbohydrate metabolism enzymes in rats J Nutr 1973 103 93 101 4682455
20 Miao J Haas JT Manthena P Hepatic insulin receptor deficiency impairs the SREBP-2 response to feeding and statins J Lipid Res 2014 55 659 667 24516236
21 Naples M Federico LM Xu E Nelken J Adeli K Effect of rosuvastatin on insulin sensitivity in an animal model of insulin resistance: evidence for statin-induced hepatic insulin sensitization Atherosclerosis 2008 198 94 103 18093597
22 Lalli CA Pauli JR Prada PO Statin modulates insulin signaling and insulin resistance in liver and muscle of rats fed a high-fat diet Metabolism 2008 57 57 65 18078859
23 Gotoh S Negishi M Statin-activated nuclear receptor PXR promotes SGK2 dephosphorylation by scaffolding PP2C to induce hepatic gluconeogenesis Sci Rep 2015 5 14076 26392083
24 Black RN Ennis CN Young IS Hunter SJ Atkinson AB Bell PM The peroxisome proliferator-activated receptor alpha agonist fenofibrate has no effect on insulin sensitivity compared to atorvastatin in type 2 diabetes mellitus; a randomised, double-blind controlled trial J Diabetes Complications 2014 28 323 327 24560135
25 Szendroedi J Anderwald C Krssak M Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients Diabetes Care 2009 32 209 214 18957532
26 Zhao W Zhao SP Different effects of statins on induction of diabetes mellitus: an experimental study Drug Des Devel Ther 2015 9 6211 6223
27 Coppieters KT Wiberg A Amirian N Kay TW von Herrath MG Persistent glucose transporter expression on pancreatic beta cells from longstanding type 1 diabetic individuals Diabetes Metab Res Rev 2011 27 746 754 22069254
28 Liang Y Cushman SM Whitesell RR Matschinsky FM GLUT1 is adequate for glucose uptake in GLUT2-deficient insulin-releasing β-cells Horm Metab Res 1997 29 255 260 9230344
29 Fex M Nicholas LM Vishnu N The pathogenetic role of β-cell mitochondria in type 2 diabetes J Endocrinol 2018 236 R145 59 29431147
30 Zhang Y Feng F Chen T Li Z Shen QW Antidiabetic and antihyperlipidemic activities of Forsythia suspensa (Thunb.) Vahl (fruit) in streptozotocin-induced diabetes mice J Ethnopharmacol 2016 192 256 263 27377336
31 Hao M Head WS Gunawardana SC Hasty AH Piston DW Direct effect of cholesterol on insulin secretion: a novel mechanism for pancreatic beta-cell dysfunction Diabetes 2007 56 2328 2338 17575085
32 The Human Protein Atlas Gene information: LDLR [Internet] place unknown The Human Protein Atlas cited 2018 Aug Available from https://www.proteinatlas.org/ENSG00000130164-LDLR/tissue
33 Ivarsson R Quintens R Dejonghe S Redox control of exocytosis: regulatory role of NADPH, thioredoxin, and glutaredoxin Diabetes 2005 54 2132 2142 15983215
34 Henquin JC Triggering and amplifying pathways of regulation of insulin secretion by glucose Diabetes 2000 49 1751 1760 11078440
35 MacDonald MJ Longacre MJ Langberg EC Decreased levels of metabolic enzymes in pancreatic islets of patients with type 2 diabetes Diabetologia 2009 52 1087 1091 19296078
36 Lupi R Marselli L Dionisi S Improved insulin secretory function and reduced chemotactic properties after tissue culture of islets from type 1 diabetic patients Diabetes Metab Res Rev 2004 20 246 251 15133757
37 Anello M Lupi R Spampinato D Functional and morphological alterations of mitochondria in pancreatic beta cells from type 2 diabetic patients Diabetologia 2005 48 282 289 15654602
38 Brand MD Parker N Affourtit C Mookerjee SA Azzu V Mitochondrial uncoupling protein 2 in pancreatic β-cells Diabetes Obes Metab 2010 12 Suppl 2 134 140 21029310
39 Yang C Zhao D Liu G Atorvastatin attenuates metabolic remodeling in ischemic myocardium through the downregulation of UCP2 expression Int J Med Sci 2018 15 517 527 29559841
40 Wang L Lin R Guo L Hong M Rosuvastatin relieves myocardial ischemia/reperfusion injury by upregulating PPAR-γ and UCP2 Mol Med Rep 2018 18 789 798 29845235
41 Urbano F Bugliani M Filippello A Atorvastatin but not pravastatin impairs mitochondrial function in human pancreatic islets and rat β-cells. Direct effect of oxidative stress Sci Rep 2017 7 11863 28928397
42 Yaluri N Modi S López Rodríguez M Simvastatin impairs insulin secretion by multiple mechanisms in MIN6 cells PLoS One 2015 10 e0142902 26561346
43 Salunkhe VA Elvstam O Eliasson L Wendt A Rosuvastatin treatment affects both basal and glucose-induced insulin secretion in INS-1 832/13 cells PLoS One 2016 11 e0151592 26986474
44 Zaki NM Strategies for oral delivery and mitochondrial targeting of CoQ10 Drug Deliv 2016 23 1868 1881 25544601
45 Chew GT Watts GF Coenzyme Q10 and diabetic endotheliopathy: oxidative stress and the ‘recoupling hypothesis’ QJM 2004 97 537 548 15256611
46 Tomita T Apoptosis in pancreatic β-islet cells in Type 2 diabetes Bosn J Basic Med Sci 2016 16 162 179 27209071
47 Sadighara M Amirsheardost Z Minaiyan M Toxicity of atorvastatin on pancreas mitochondria: a justification for increased risk of diabetes mellitus Basic Clin Pharmacol Toxicol 2017 120 131 137 27553485
48 Chen ZY Liu SN Li CN Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress Lipids Health Dis 2014 13 98 24950764
49 Otani M Yamamoto M Harada M Otsuki M Effect of long- and short-term treatments with pravastatin on diabetes mellitus and pancreatic fibrosis in the Otsuka-Long-Evans-Tokushima fatty rat Br J Pharmacol 2010 159 462 473 20015084
50 Lorza-Gil E Salerno AG Wanschel AC Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice Toxicology 2016 344-346 42 52 26875785
51 Contreras JL Smyth CA Bilbao G Young CJ Thompson JA Eckhoff DE Simvastatin induces activation of the serine-threonine protein kinase AKT and increases survival of isolated human pancreatic islets Transplantation 2002 74 1063 1069 12438947
52 Mohammed A Qian L Janakiram NB Lightfoot S Steele VE Rao CV Atorvastatin delays progression of pancreatic lesions to carcinoma by regulating PI3/AKT signaling in p48 Cre/+ LSL-Kras G12D/+ mice Int J Cancer 2012 131 1951 1962 22287227
53 Favaro E Miceli I Bussolati B Hyperglycemia induces apoptosis of human pancreatic islet endothelial cells: effects of pravastatin on the Akt survival pathway Am J Pathol 2008 173 442 450 18599614
54 De Meyts P The insulin receptor and its signal transduction network De Groot LJ Chrousos G Dungan K Endotext [Internet] South Dartmouth (MA) MDText.com, Inc. 2000- updated 2016 Apr 27 cited 2018 Aug Available from https://www.ncbi.nlm.nih.gov/books/NBK378978/
55 Jiang Z Yu B Li Y Effect of three statins on glucose uptake of cardiomyocytes and its mechanism Med Sci Monit 2016 22 2825 2830 27510725
56 Li W Liang X Zeng Z Simvastatin inhibits glucose uptake activity and GLUT4 translocation through suppression of the IR/IRS-1/Akt signaling in C2C12 myotubes Biomed Pharmacother 2016 83 194 200 27470565
57 Yaluri N Modi S Kokkola T Simvastatin induces insulin resistance in L6 skeletal muscle myotubes by suppressing insulin signaling, GLUT4 expression and GSK-3β phosphorylation Biochem Biophys Res Commun 2016 480 194 200 27743890
58 Chamberlain LH Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes FEBS Lett 2001 507 357 361 11696371
59 Takaguri A Satoh K Itagaki M Tokumitsu Y Ichihara K Effects of atorvastatin and pravastatin on signal transduction related to glucose uptake in 3T3L1 adipocytes J Pharmacol Sci 2008 107 80 89 18469500
60 Khan T Hamilton MP Mundy DI Chua SC Scherer PE Impact of simvastatin on adipose tissue: pleiotropic effects in vivo Endocrinology 2009 150 5262 5272 19819942
61 Sahebkar A Simental-Mendía LE Pedone C Statin therapy and plasma free fatty acids: a systematic review and meta-analysis of controlled clinical trials Br J Clin Pharmacol 2016 81 807 818 26624855
62 Berk-Planken II Hoogerbrugge N Stolk RP Bootsma AH Jansen H DALI Study Group Atorvastatin dose-dependently decreases hepatic lipase activity in type 2 diabetes: effect of sex and the LIPC promoter variant Diabetes Care 2003 26 427 432 12547874
63 Bey L Maigret P Laouenan H Hamilton MT Induction of lipoprotein lipase gene expression in 3T3-L1 preadipocytes by atorvastatin, a cholesterol- and triglyceride-lowering drug Pharmacology 2002 66 51 56 12169766
64 Ohira M Endo K Saiki A Atorvastatin and pitavastatin enhance lipoprotein lipase production in L6 skeletal muscle cells through activation of adenosine monophosphate-activated protein kinase Metabolism 2012 61 1452 1460 22520230
65 Roden M How free fatty acids inhibit glucose utilization in human skeletal muscle News Physiol Sci 2004 19 92 96 15143200
66 Williams ML Menon GK Hanley KP HMG-CoA reductase inhibitors perturb fatty acid metabolism and induce peroxisomes in keratinocytes J Lipid Res 1992 33 193 208 1569372
67 Murthy S Tong H Hohl RJ Regulation of fatty acid synthesis by farnesyl pyrophosphate J Biol Chem 2005 280 41793 41804 16221687
68 Chruściel P Sahebkar A Rembek-Wieliczko M Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms Atherosclerosis 2016 253 194 208 27498397
69 Sahebkar A Giua R Pedone C Impact of statin therapy on plasma leptin concentrations: a systematic review and meta-analysis of randomized placebo-controlled trials Br J Clin Pharmacol 2016 82 1674 1684 27509867
70 Sahebkar A Giorgini P Ludovici V Impact of statin therapy on plasma resistin and visfatin concentrations: a systematic review and meta-analysis of controlled clinical trials Pharmacol Res 2016 111 827 837 27468651
71 Singh P Zhang Y Sharma P Statins decrease leptin expression in human white adipocytes Physiol Rep 2018 6 e13566
72 Kralova Lesna I Petras M Cejkova S Cardiovascular disease predictors and adipose tissue macrophage polarization: is there a link? Eur J Prev Cardiol 2018 25 328 334 29154680
73 Abe M Matsuda M Kobayashi H Effects of statins on adipose tissue inflammation: their inhibitory effect on MyD88-independent IRF3/IFN-β pathway in macrophages Arterioscler Thromb Vasc Biol 2008 28 871 877 18323514
74 Henriksbo BD Schertzer JD Is immunity a mechanism contributing to statin-induced diabetes? Adipocyte 2015 4 232 238 26451278
75 Henriksbo BD Lau TC Cavallari JF Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance Diabetes 2014 63 3742 3747 24917577
76 Singh LP The NLRP3 inflammasome and diabetic cardiomyopathy: editorial to: “Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model” by Beibei Luo et al Cardiovasc Drugs Ther 2014 28 5 6 24220800
77 Luo B Li B Wang W Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model Cardiovasc Drugs Ther 2014 28 33 43 24254031
78 Altaf A Qu P Zhao Y Wang H Lou D Niu N NLRP3 inflammasome in peripheral blood monocytes of acute coronary syndrome patients and its relationship with statins Coron Artery Dis 2015 26 409 421 25946654
79 Kong F Ye B Lin L Cai X Huang W Huang Z Atorvastatin suppresses NLRP3 inflammasome activation via TLR4/MyD88/NF-κB signaling in PMA-stimulated THP-1 monocytes Biomed Pharmacother 2016 82 167 172 27470352
80 Yu SY Tang L Zhao GJ Zhou SH Statin protects the heart against ischemia-reperfusion injury via inhibition of the NLRP3 inflammasome Int J Cardiol 2017 229 23 24 27865664
81 Wang S Xie X Lei T Statins attenuate activation of the NLRP3 inflammasome by oxidized LDL or TNFα in vascular endothelial cells through a PXR-dependent mechanism Mol Pharmacol 2017 92 256 264 28546421
82 Gazzerro P Proto MC Gangemi G Pharmacological actions of statins: a critical appraisal in the management of cancer Pharmacol Rev 2012 64 102 146 22106090
*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.
오픈액세스 학술지에 출판된 논문
Copyright KISTI. All Rights Reserved.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.